Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: Results of the randomized noninferiority Euro-EWING99-R1 trial

Journal of Clinical Oncology

Volumn 32, Issue 23, 2014, Pages 2440-2448

  Le Deley, Marie Cécile ^b   Paulussen, Michael ^e   Lewis, Ian ^g   Brennan, Bernadette ^h   Ranft, Andreas ^f   Whelan, Jeremy ⁱ   Le Teuff, Gwénaël ^p   Michon, Jean ^c   Ladenstein, Ruth ^m   Marec Bérard, Perrine ^d   Van Den Berg, Henk ⁿ   Hjorth, Lars ^o   Wheatley, Keith ^k   Judson, Ian ^j   Juergens, Heribert ^f   Craft, Alan ^l   Oberlin, Odile ^a   Dirksen, Uta ^f  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSTITUT CURIE   (France)

^d CENTRE LÉON BÉRARD   (France)

^e UNIVERSITY OF WITTEN HERDECKE   (Germany)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^g ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^h ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^j ROYAL MARSDEN HOSPITAL   (United Kingdom)

^k UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^l ROYAL VICTORIA INFIRMARY   (United Kingdom)

^m St Anna Children's Cancer Research Institute   (Austria)

ⁿ EMMA CHILDREN S HOSPITAL   (Netherlands)

^o LUND UNIVERSITY HOSPITAL   (Sweden)

^p NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; CREATININE; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PROTOCOL; COMPARATIVE EFFECTIVENESS; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; EWING SARCOMA; FEMALE; FOLLOW UP; GLOMERULAR DYSFUNCTION; HEALTH CARE QUALITY; HEART LEFT VENTRICLE FAILURE; HEMATURIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; INDUCTION CHEMOTHERAPY; INFECTION; LEUKOPENIA; LOCAL THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; PARALLEL DESIGN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUBULAR DYSFUNCTION; TUMOR DIAGNOSIS; TUMOR LOCALIZATION; BONE NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MULTICENTER STUDY; SARCOMA, EWING; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CONSOLIDATION CHEMOTHERAPY; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; MALE; SARCOMA, EWING; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84905851588     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.4833     Document Type: Article

References (30)

1. Nesbit ME Jr, Perez CA, Tefft M, et al: Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: An Intergroup Study. Natl Cancer Inst Monogr 56:255-262, 1981 (Pubitemid 12193869)
2. Oberlin O, Deley MC, Bui BN, et al: Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: The third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer 85:1646-1654, 2001 (Pubitemid 34081507)
3. Jürgens H, Exner U, Gadner H, et al: Multidisciplinary treatment of primary Ewing's sarcoma of bone: A 6-year experience of a European Cooperative Trial. Cancer 61:23-32, 1988 (Pubitemid 18023106)
4. Ruymann FB, Vietti T, Gehan E, et al: Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma: A pilot study without hematopoietic growth factor support evaluating toxicity and response. J Pediatr Hematol Oncol 17:331-337, 1995
5. Carli M, Passone E, Perilongo G, et al: Ifosfamide in pediatric solid tumors. Oncology 65:99-104, 2003 (suppl 2)
6. Bramwell VH, Mouridsen HT, Santoro A, et al: Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 23:311-321, 1987 (Pubitemid 17033680)
7. Grier HE, Krailo MD, Tarbell NJ, et al: Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348:694-701, 2003 (Pubitemid 36237038)
8. Craft A, Cotterill S, Malcolm A, et al: Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. J Clin Oncol 16:3628-3633, 1998 (Pubitemid 28506777)
9. Oberlin O, Habrand JL, Zucker JM, et al: No benefit of ifosfamide in Ewing's sarcoma: A nonrandomized study of the French Society of Pediatric Oncology. J Clin Oncol 10:1407-1412, 1992 (Pubitemid 23059923)
10. Paulussen M, Ahrens S, Dunst J, et al: Localized Ewing tumor of bone: Final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol 19:1818-1829, 2001 (Pubitemid 32230885)
11. Suarez A, McDowell H, Niaudet P, et al: Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: An International Society of Pediatric Oncology report. J Clin Oncol 9:2177-2182, 1991
12. Skinner R, Pearson AD, Coulthard MG, et al: Assessment of chemotherapy-associated nephrotoxicity in children with cancer. Cancer Chemother Pharmacol 28:81-92, 1991
13. Paulussen M, Craft AW, Lewis I, et al: Results of the EICESS-92 Study: Two randomized trials of Ewing's sarcoma treatment-Cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 26:4385-4393, 2008
14. Strauss SJ, McTiernan A, Driver D, et al: Single center experience of a new intensive induction therapy for Ewing's family of tumors: Feasibility, toxicity, and stem cell mobilization properties. J Clin Oncol 21:2974-2981, 2003 (Pubitemid 46621850)
15. Juergens C, Weston C, Lewis I, et al: Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer 47:22-29, 2006 (Pubitemid 43787904)
16. Cancer Therapy Evaluation Program. Common toxicity criteria. http://search.babylon.com/?q=how+to+refer+Cancer+therapy+evaluation+program. +Common+toxicity+criteria%2C+Version+2+0.+1998.Dctd%2C+nci%2C+nih%2C+dhhs%2C. +1998+p.&s=web&as=0&rlz=0&babsrc=NT-ss
17. Com-Nougué C, Guérin S, Rey A: Assessment of risks associated with multiple events [in French]. Rev Epidemiol Sante Publique 47:75-85, 1999 (Pubitemid 29156303)
18. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35:549-556, 1979 (Pubitemid 10242750)
19. Piaggio G, Elbourne DR, Altman DG, et al: Reporting of noninferiority and equivalence randomized trials: An extension of the CONSORT statement. JAMA 295:1152-1160, 2006 (Pubitemid 43352345)
20. Fine JP, Gray R: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
21. Matilde Sanchez M, Chen X: Choosing the analysis population in non-inferiority studies: Per protocol or intent-to-treat. Stat Med 25:1169-1181, 2006
22. Fayers PM, Ashby D, Parmar MK: Tutorial in biostatistics Bayesian data monitoring in clinical trials. Stat Med 16:1413-1430, 1997 (Pubitemid 27292273)
23. Oberlin O, Fawaz O, Rey A, et al: Long-term evaluation of ifosfamide-related nephrotoxicity in children. J Clin Oncol 27:5350-5355, 2009
24. Skinner R: Chronic ifosfamide nephrotoxicity in children. Med Pediatr Oncol 41:190-197, 2003
25. Kenney LB, Laufer MR, Grant FD, et al: High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood. Cancer 91:613-621, 2001 (Pubitemid 32105709)
26. Meistrich ML, Wilson G, Brown BW, et al: Impact of cyclophosphamide on long-term reduction in sperm count in men treated with combination chemotherapy for Ewing and soft tissue sarcomas. Cancer 70:2703-2712, 1992
27. Ridola V, Fawaz O, Aubier F, et al: Testicular function of survivors of childhood cancer: A comparative study between ifosfamide- and cyclophospha-mide- based regimens. Eur J Cancer 45:814-818, 2009
28. Williams D, Crofton PM, Levitt G: Does ifosfamide affect gonadal function? Pediatr Blood Cancer 50:347-351, 2008
29. Granowetter L, Womer R, Devidas M, et al: Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: A Children's Oncology Group Study. J Clin Oncol 27:2536-2541, 2009
30. Womer RB, West DC, Krailo MD, et al: Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: A report from the Children's Oncology Group. J Clin Oncol 30:4148-4154, 2012 Forschung